Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.

40 participants will be selected based on eligibility criteria and collected information, then, randomly separated into two groups. All participants will sign informed consent form, monitor vital signs, laboratory examination (CT/MRI, blood routine examination, urine routine examination, liver function, renal function, etc.), NIHSS, Fugl-Meyer analysis (FMA) 0-3 days before treatment. All of them will receive basic treatment with Aspirin Enteric-coated Tablets and Atorvastatin Calcium. And experimental group will treat with hUC-MSC, control group with placebo (normal saline) on the 7th and 14th day. After the treatment, investigator will follow-up, monitor vital signs, laboratory examination, NIHSS, FMA analysis on 2 weeks, 1 month, and 6 months after the treatment.

• Allogeneic umbilical cord mesenchymal stem cell (Biological): Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
• Aspirin Enteric-coated Tablets & Atorvastatin Calcium (Drug): Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.

Primary outcomes

• Motor function analysis [6 months]: Based on Activity of Daily Living Scale (ADL) to analysis efficacy of cell treatment.The score of patient with upper limb >60, and total score >90 is considered good recovery.

Secondary outcomes

• Neurological deficits analysis [6 months]: According to Chinese scale of clinical neurologic deficit to analysis, the result as follow: * Excellent: after treatment, patient with consciousness, and clinical symptoms improved; * Effective: vital signs and main symptoms in remission; * Inefficient: no obvious improvement or condition worsened.
• Limb motor function analysis [6 months]: Using fugl-meyer assessment evaluate motor function. Mild movement disorder: 96 - 99; Moderate movement disorder: 85 - 95; Obvious movement disorder: 50 - 84; Serious movement disorder: < 50
• Barthel Index analysis [6 months]: Obvious effective: Barthel Index score between 96 - 99, patient with self care ability. Effective:Barthel Index score between 70 - 89, patient with condition improved. Invalid: The effect do not meet above standards.

Sex: All, ages: 20 Years to 75 Years

Inclusion Criteria:

* proved cerebral infarction by CT or MRI.
* no cerebrovascular disease before
* signed informed consent form

Exclusion Criteria:

* serious body and intracranial lesions (tumor, infection, etc.)
* patients repeated cerebral infarction attacks
* multi-foci of cerebral infarction
* history of drug dependence and mental disease
* disturbance of consciousness and non-compliance patients
* subjects who are HIV positive
* pregnant or lactation
* donor: HIV infected, Active hepatitis B/C infected, Syphilis antibody positive
* subjects/ donor: alcoholism, drug addicts or mental disease

• Wulan, Study director, Inner Mongolia International Mongolian Hospital
• Lei Guo, Dr, Study chair, China-Japan Union Hospital, Jilin University